MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma

Abstract Hepatoblastoma (HB) is the most common pediatric liver malignancy. High-risk patients have poor survival, and current chemotherapies are associated with significant toxicities. Targeted therapies are needed to improve outcomes and patient quality of life. Most HB cases are TP53 wild-type; t...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sarah E. Woodfield, Yan Shi, Roma H. Patel, Zhenghu Chen, Aayushi P. Shah, Richard S. Whitlock, Aryana M. Ibarra, Samuel R. Larson, Stephen F. Sarabia, Andrew Badachhape, Zbigniew Starosolski, Ketan B. Ghaghada, Pavel Sumazin, D. Allen Annis, Dolores López-Terrada, Sanjeev A. Vasudevan
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/2c835b5e701047a99457ad48818f16a6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!